Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Shares Outstanding (Weighted Average) (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Shares Outstanding (Weighted Average) for 2 consecutive years, with $16.3 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Shares Outstanding (Weighted Average) rose 54.39% year-over-year to $16.3 million, compared with a TTM value of $16.3 million through Jun 2025, up 54.39%, and an annual FY2024 reading of $11.4 million, changed N/A over the prior year.
  • Shares Outstanding (Weighted Average) was $16.3 million for Q2 2025 at Kairos Pharma, up from $15.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $16.3 million in Q2 2025 and bottomed at $10.6 million in Q1 2024.